The Asilomar Conference of 1975 and the German Ethics Council offer guidance for a path towards prudent regulation in the face of unknown and significant risks.
AMA J Ethics. 2019;21(12):E1042-1048. doi:
10.1001/amajethics.2019.1042.
Although advisory groups like the World Health Organization question whether certain forms of gene editing should be permitted, the US Patent Office routinely issues patents protecting this technology.
AMA J Ethics. 2019;21(12):E1049-1055. doi:
10.1001/amajethics.2019.1049.
Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
We live in a time when an array of information is available at the fingertips of anyone with access to a computer, but more information doesn’t necessarily mean more understanding. False beliefs about health care can be quickly and widely perpetuated online, with serious consequences. This month on Ethics Talk, we spoke with Dr. Jennifer McCormick, Dr. Albert Ko, and Dr. Diane Griffin about why it’s important for clinicians to respond to health care-related false beliefs and how they can do so effectively.
In a special mini-episode of Ethics Talk, we explore the implications of a new proposed immigration policy that could have broad effects on immigrants' health with Dr. Rachel Fabi, explain why clinicians and students should consider submitting a public comment, and outline best practices for weighing in.